Literature DB >> 24931711

High-density lipoprotein subfractions: current views and clinical practice applications.

Seth S Martin1, Steven R Jones1, Peter P Toth2.   

Abstract

High-density lipoprotein (HDL) is astonishingly complex, but the de facto standard for its measurement has been remarkably simple: total cholesterol content. It is time to prioritize higher-resolution HDL measurement techniques that capture better the biologically and clinically important characteristics of HDL. Scientific advances have ushered in a new era in which we view HDL in terms of its subfractions, particle structure, metabolism, and functional integration of its proteome and lipidome. HDL subfractions appear to be associated with function. In general, smaller, denser HDL3 is more tightly linked to favorable atheroprotective functions and clinical outcomes. Techniques to measure the cholesterol content or particle concentrations of HDL subfractions are available clinically. In the future, we anticipate subfractionating HDL based on its functional properties.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cholesterol; function; high-density lipoprotein (HDL); particles; subfractions

Mesh:

Substances:

Year:  2014        PMID: 24931711     DOI: 10.1016/j.tem.2014.05.005

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  18 in total

1.  APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.

Authors:  Orlando M Gutiérrez; Suzanne E Judd; Marguerite R Irvin; Degui Zhi; Nita Limdi; Nicholette D Palmer; Stephen S Rich; Michèle M Sale; Barry I Freedman
Journal:  Nephrol Dial Transplant       Date:  2015-07-06       Impact factor: 5.992

Review 2.  ABCA1 and nascent HDL biogenesis.

Authors:  Shuhui Wang; Jonathan D Smith
Journal:  Biofactors       Date:  2014-10-30       Impact factor: 6.113

3.  Is it time to change the goals of lipid management in type 1 diabetes mellitus? Changes in apolipoprotein levels during the first year of type 1 diabetes mellitus. Prospective InLipoDiab1 study.

Authors:  Aleksandra Cieluch; Aleksandra Uruska; Marcin Nowicki; Ewa Wysocka; Paweł Niedźwiecki; Agata Grzelka-Woźniak; Justyna Flotyńska; Dorota Zozulińska-Ziółkiewicz
Journal:  Arch Med Sci       Date:  2020-10-29       Impact factor: 3.707

4.  High-Density Lipoproteins for Therapeutic Delivery Systems.

Authors:  R Kannan Mutharasan; Linda Foit; C Shad Thaxton
Journal:  J Mater Chem B       Date:  2015-11-24       Impact factor: 6.331

5.  High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort.

Authors:  Robert W McGarrah; Damian M Craig; Carol Haynes; Z Elaine Dowdy; Svati H Shah; William E Kraus
Journal:  Atherosclerosis       Date:  2016-01-11       Impact factor: 5.162

6.  Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol.

Authors:  Marios K Georgakis; Rainer Malik; Christopher D Anderson; Klaus G Parhofer; Jemma C Hopewell; Martin Dichgans
Journal:  Brain       Date:  2020-02-01       Impact factor: 13.501

7.  High-density lipoprotein and endothelial function in patients with myocardial infarction: Pieces in a puzzle.

Authors:  Seth S Martin; Parag H Joshi; Michael J Blaha
Journal:  Atherosclerosis       Date:  2014-10-22       Impact factor: 6.847

8.  Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Khanh N Vu; Christie M Ballantyne; Ron C Hoogeveen; Vijay Nambi; Kelly A Volcik; Eric Boerwinkle; Alanna C Morrison
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

9.  Serum uric acid is associated with increased risk of idiopathic venous thromboembolism in high HDL-C population: A case-control study.

Authors:  Miao Yu; Ken Ling; Yunfei Teng; Qin Li; Fei Mei; Yiqing Li; Chenxi Ouyang
Journal:  Exp Ther Med       Date:  2016-04-05       Impact factor: 2.447

Review 10.  Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease.

Authors:  Clementina Mesaros; Ian A Blair
Journal:  Clin Proteomics       Date:  2016-10-05       Impact factor: 3.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.